Ftse Mib
34.150,54
-1,47%
DAX
18.473,29
-1,13%
S&P 500
5.266,95
-0,74%
NASDAQ
16.920,58
-0,58%
Bitcoin
68.102,28
0,77%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSXV Diamedica Therapeutics (DMA) Diamedica Therapeutics (DMA) Notizie

DMA

DiaMedica Inc. (DMA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSXV:DMA
DataOraFonteTitoloSimboloCompagnia
30/07/201414:00Marketwired CanadaDiaMedica to Present at InvestMNt Conference on August 6, 2014TSXV:DMADiamedica Therapeutics
25/07/201422:30Marketwired CanadaDiaMedica Inc. Announces Results of Annual General and Special Meeting of ShareholdersTSXV:DMADiamedica Therapeutics
10/07/201414:30Marketwired CanadaDiaMedica Promotes Mark Robbins to Executive Vice PresidentTSXV:DMADiamedica Therapeutics
08/07/201423:09Marketwired CanadaDiaMedica Announces Stock Option GrantTSXV:DMADiamedica Therapeutics
07/07/201414:30Marketwired CanadaDiaMedica Appoints Rich Pilnik as Chairman of the Board of DirectorsTSXV:DMADiamedica Therapeutics
10/06/201413:30Marketwired CanadaDiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association ConferenceTSXV:DMADiamedica Therapeutics
05/06/201416:22Marketwired CanadaDiaMedica Announces Development UpdateTSXV:DMADiamedica Therapeutics
03/06/201416:56Marketwired CanadaDiaMedica Inc. Appoints Dr. Ralph A. DeFronzo to its Scientific Advisory BoardTSXV:DMADiamedica Therapeutics
27/05/201417:53Marketwired CanadaDiaMedica Announces Completion of Prospectus OfferingTSXV:DMADiamedica Therapeutics
20/05/201422:22Marketwired CanadaDiaMedica Inc. Announces Filing of Final ProspectusTSXV:DMADiamedica Therapeutics
13/05/201400:26Marketwired CanadaDiaMedica Inc. Finalizes Terms of Public OfferingTSXV:DMADiamedica Therapeutics
08/05/201413:05Marketwired CanadaDiaMedica Inc. Provides Update on Public OfferingTSXV:DMADiamedica Therapeutics
25/04/201423:50Marketwired CanadaDiaMedica Inc. Amends the Expiry Date of WarrantsTSXV:DMADiamedica Therapeutics
22/04/201422:05Marketwired CanadaDiaMedica Inc. Announces Public OfferingTSXV:DMADiamedica Therapeutics
17/04/201415:28Marketwired CanadaDiaMedica Inc. to Amend the Expiry Date of WarrantsTSXV:DMADiamedica Therapeutics
15/04/201415:00Marketwired CanadaDiaMedica to Present at the 2014 GTC Diabetes SummitTSXV:DMADiamedica Therapeutics
07/04/201415:07MarketwiredDiaMedica Appoints John Savage as Chief Financial OfficerTSXV:DMADiamedica Therapeutics
25/03/201417:14Marketwired CanadaGranite Creek Cancels Consulting AgreementTSXV:DMADiamedica Therapeutics
19/02/201414:30MarketwiredDiaMedica Files 20-F Registration Statement with U.S. SEC and Provides Clinical UpdateTSXV:DMADiamedica Therapeutics
05/02/201418:15MarketwiredDiaMedica to Present at 16th Annual BIO CEO & Investor ConferenceTSXV:DMADiamedica Therapeutics
22/01/201423:10Marketwired CanadaDiaMedica Inc. Announces Partial Exercise of Over-Allotment OptionTSXV:DMADiamedica Therapeutics
09/01/201414:30MarketwiredDiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic PatientsTSXV:DMADiamedica Therapeutics
03/01/201415:44Marketwired CanadaDiaMedica Inc. Closes Non-Brokered Private PlacementTSXV:DMADiamedica Therapeutics
23/12/201314:26Marketwired CanadaDiaMedica Inc. Announces Completion of $2.6 Million Prospectus OfferingTSXV:DMADiamedica Therapeutics
20/12/201323:50MarketwiredDiaMedica Inc. Announces Results of Annual General and Special MeetingTSXV:DMADiamedica Therapeutics
20/11/201315:11Marketwired CanadaDiaMedica to Present at the 25th Annual Piper Jaffray HealthcareTSXV:DMADiamedica Therapeutics
11/11/201322:00Marketwired CanadaDiaMedica Issues Stock Option GrantTSXV:DMADiamedica Therapeutics
30/10/201313:00Marketwired CanadaDiaMedica's DM199 Named One of the Top Ten Cardiovascular/Metabolic Disease Projects to WatchTSXV:DMADiamedica Therapeutics
30/09/201314:30Marketwired CanadaDiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic PatientsTSXV:DMADiamedica Therapeutics
30/08/201318:03Marketwired CanadaGranite Creek Retains Marketing ConsultantsTSXV:DMADiamedica Therapeutics
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSXV:DMA

La tua Cronologia

BIT
CUBE
Cube Labs
NASDAQ
LCOMX
Legal & General Commodit...
LBNK
MDFCUSDT
MDFC
LSE
GABC
BIT
F18118
Vontobel Financial Produ...
LSE
SCRM
Ls -1x Crm
BOV
KFOF11
Fundo DE Fundos DE Inves...
BIT
F18724
Vontobel Financial Produ...
NYSE
DTQ
DTE Energy
BITMOT
915685
World Bank Green Bond Tf...
NYSE
MTUS
Metallus
BIT
SPAB
Global X S&p 500 Annual ...
BIT
F16659
Vontobel Financial Produ...
COIN
WABUSD
WABnetwork
LSE
44EK
Orbit 3.375%
USOTC
OXFYY
Oxford Nanopore Technolo... (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network